While the Beat-AML and the ELN 2024 mPRS are predicting survival, the Mayo score has been developed as a predictor of treatment response and categorized patients in four molecular signatures based on a six-gene panel (NPM1, IDH2, DDX41, TP53, RUNX1, and FLT3-ITD). Here, IDH2 is linked to acute myeloid leukemia.